Prenostics

Prenostics is pioneering a paradigm shift in oncology through its proprietary blood test designed to detect stage 0-2 cancers, a capability claimed to be years ahead of current diagnostic standards. Founded by Oxford Professor Sarah Blagden, the company leverages a novel biomarker to enable early intervention and curative treatment pathways. With an experienced leadership team blending deep scientific expertise and commercial diagnostics experience, Prenostics is initially targeting high-risk ovarian cancer and indeterminate lung nodules. The company is a private, pre-revenue entity positioned in the high-growth, high-impact field of multi-cancer early detection.

Blood-based assay detecting a novel biomarker for stage 0-2 cancer, enabling detection years before conventional methods.

Prenostics operates in the highly competitive liquid biopsy and multi-cancer early detection space, competing with large players like Grail (Illumina), Exact Sciences, and Freenome. Its differentiation lies in its specific claim of detecting cancer at stage 0-2 and its focused initial indications, rather than a broad, population-wide screening test.